Doxorubicin plus Ifosfamide as Salvage Treatment for Patients with Advanced Breast Cancer Refractory to Epirubicin plus Cyclophosphamide

被引：0

作者：

Aristidis Polyzos

C. Kosmas

N. Tsavaris

C. Markopoulos

N. Kalahanis

O. Papadopoulos

T. Arnaouti

P. P. Sfikakis

机构：

[1] Athens University School of Medicine,First Department of Propaedeutic Medicine

[2] Laikon Hospital,Medical Oncology Unit

[3] Goudi,Department of Pathophysiology

[4] Helena Venizelou Hospital,Department of Surgery

[5] Athens University School of Medicine,undefined

[6] Laikon Hospital,undefined

[7] Athens University School of Medicine,undefined

[8] Laikon Hospital,undefined

来源：

Clinical Drug Investigation | 2000年 / 19卷

关键词：

Breast Cancer; Paclitaxel; Doxorubicin; Epirubicin; Advanced Breast Cancer;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Objective: To investigate the response and toxicity of a salvage regimen in patients with advanced breast cancer whose tumours became resistant to fluorouracil-epirubicin-cyclophosphamide (FEC). By substituting doxorubicin for epirubicin and ifosfamide for cyclophosphamide, we aimed to evaluate the possible lack of cross-resistance between the two anthracyclines and the two alkylating agents.

引用

页码：349 / 355

页数：6

共 50 条

[1] Doxorubicin plus ifosfamide as salvage treatment for patients with advanced breast cancer refractory to epirubicin plus cyclophosphamide
Polyzos, A
Kosmas, C
Tsavaris, N
Markopoulos, C
Kalahanis, N
Papadopoulos, O
Arnaouti, T
Sfikakis, PP
CLINICAL DRUG INVESTIGATION, 2000, 19 (05) : 349 - 355
[2] Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer
Diéras, V
Fumoleau, P
Romieu, G
Tubiana-Hulin, M
Namer, M
Mauriac, L
Guastalla, JP
Pujade-Lauraine, E
Kerbrat, P
Maillart, P
Pénault-Llorca, F
Buyse, M
Pouillart, P
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (24) : 4958 - 4965
[3] Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor
Werner Kwasny
Gabriela Kornek
Karin Haider
Julia Valencak
Herbert Ulrich-Pur
Melitta Penz
Friedrich Lang
Dieter Depisch
Werner Scheithauer
Breast Cancer Research and Treatment, 2000, 63 : 235 - 241
[4] Treatment of advanced, refractory breast cancer with alternating docetaxel and epirubicin/cyclophosphamide plus human granulocyte colony-stimulating factor
Kwasny, W
Kornek, G
Haider, K
Valencak, J
Ulrich-Pur, H
Penz, M
Lang, F
Depisch, D
Scheithauer, W
BREAST CANCER RESEARCH AND TREATMENT, 2000, 63 (03) : 235 - 241
[5] Epirubicin, cyclophosphamide, and UFT plus oral calcium folinate in advanced breast cancer
Smith, IE
ONCOLOGY-NEW YORK, 1999, 13 (07): : 82 - 85
[6] UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer
Gregory, RK
Johnston, SRD
Smith, IE
Miles, D
ONCOLOGY-NEW YORK, 2000, 14 (10): : 47 - 49
[7] Paclitaxel plus epirubicin in advanced breast cancer
Conte, PF
Gennari, A
Salvadori, B
Pazzagli, I
Bengala, C
ONCOLOGY-NEW YORK, 1998, 12 (01): : 40 - 44
[8] PHASE-II STUDY OF DOXORUBICIN PLUS IFOSFAMIDE MESNA IN PATIENTS WITH ADVANCED BREAST-CANCER
MILLWARD, MJ
HARRIS, AL
CANTWELL, BMJ
CANCER, 1990, 65 (11) : 2421 - 2425
[9] Lonidamine plus epirubicin and cyclophosphamide in advanced breast cancer. A phase II study
Gardin, G
Barone, C
Nascimben, O
Ianniello, G
Sturba, F
Contu, A
Pronzato, P
Rosso, R
EUROPEAN JOURNAL OF CANCER, 1996, 32A (01) : 176 - 177
[10] Breast conserving surgery after neoadjuvant chemotherapy paclitaxel plus doxorubicin vs fluorouracil plus doxorubicin plus cyclophosphamide in locally advanced breast cancer.
Semlglazov, VF
Bojok, AA
Arsumanov, AS
Ivanova, OA
Ivanov, VG
Semlglazov, VV
Pozharissky, KM
Topuzov, AE
Nurgaziev, KS
Paltuev, KS
Petrov, RM
BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S52 - S52

← 1 2 3 4 5 →